Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 5/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847743 | 0.93 | MAPK8 (0.51) | EDNRAMAPK8MAPK9 | |
| SCHEMBL849556 | 0.90 | MAPK8 (0.50) | MAPK8MAPK9 | |
| SCHEMBL848643 | 0.90 | MAPK8 (0.47) | MAPK8MAPK9 | |
| SCHEMBL847035 | 0.79 | PABPC1 (0.42) | MAPK8MAPK9KDM4EMAPT | |
| SCHEMBL848167 | 0.72 | EDNRA (0.60) | EDNRAMAPK8MAPK9EDNRBMAPT | |
| SCHEMBL10758715 | 0.72 | KDM4E (0.58) | EDNRAMAPK8KDM4EMAPTHTT | |
| SCHEMBL9536907 | 0.70 | KDM4E (0.54) | EDNRAMAPK8MAPK9KDM4EEDNRB | |
| SCHEMBL9539511 | 0.70 | KDM4E (0.58) | EDNRAMAPK8KDM4EMAPTHTT | |
| SCHEMBL9534704 | 0.68 | KDM4E (0.53) | EDNRAMAPK8KDM4EMAPTHTT | |
| SCHEMBL9534868 | 0.68 | MEN1 (0.54) | EDNRAMAPK8KDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | MAPK9, MAPK10, MAPK1 | EDNRA 1204/4885MAPK8 12/4885MAPK9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.